Roles of SIRT1 in tumorigenesis and tumor progression

Abstract

FU De-Qiang, WU Wen-Yi, ZHANG Li-Ting. Roles of SIRT1 in tumorigenesis and tumor progression[J]. Journal of International Oncology, 2013, 40(12): 902-904.

［1］ Dirks AJ, Leeuwenhburgh C. Tumor necrosis factor alpha signaling in skeletal muscle: effects of age and caloric restriction. J Nutr Biochem, 2006, 17(8): 501508. ［2］ Cha EJ, Noh SJ, Kwon KS, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res, 2009, 15(13): 44534459. ［3］ Jung W, Hong KD, Jung WY, et al. SIRT1 expression is associated with good prognosis in colorectal cancer. Korean J Pathol, 2013, 47(4): 332339. ［4］ Stenzinger A, Endris V, Klauschen F, et al. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. BMC Cancer, 2013, 13(1): 450. ［5］ Kuo SJ, Lin HY, Chien SY, et al. SIRT1 suppresses breast cancer growth through downregulation of the Bcl2 protein. Oncol Rep, 2013, 30(1): 125130. ［6］ Kriegl L, Vieth M, Kirchner T, et al. Upregulation of cMYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. Oncotarget, 2012, 3(10): 11821193. ［7］ Hida Y, Kubo Y, Murao K, et al. Strong expression of a longevityrelated protein, SIRT1, in Bowen′s disease. Arch Dermatol Res, 2007, 299(2): 103106. ［8］ Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2 (SIRT1) functions as an NADdependent p53 deacetylase. Cell, 2001, 107(2): 149159. ［9］ Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell, 2001, 107(2): 137148. ［10］ Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a smallmolecule p53 activator. Cancer Cell, 2008, 13(5): 454463. ［11］ Rizki G, Iwata TN, Li J, et al. The evolutionarily conserved longevity determinants HCF1 and SIR2.1/SIRT1 collaborate to regulate DAF16/FOXO. PLoS Genet, 2011, 7(9): e1002235. ［12］ Dai JM, Wang ZY, Sun DC, et al. SIRT1 interacts with p73 and suppresses p73dependent transcriptional activity. J Cell Physiol, 2007, 210(1): 161166. ［13］ Wong S, Weber JD. Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. Biochem J, 2007, 407(3): 451460. ［14］ Pruitt K, Zinn RL, Ohm JE, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet, 2006, 2(3): e40. ［15］ Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science, 2004, 305(5682): 390392. ［16］ Yuan Z, Zhang X, Sengupta N, et al. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol Cell, 2007, 27(1): 149162. ［17］ Li K, Casta A, Wang R, et al. Regulation of WRN protein cellular localization and enzymatic activities by SIRT1mediated deacetylation. J Biol Chem, 2008, 283(12): 75907598. ［18］ Deng CX. SIRT1, is it a tumor promoter or tumor suppressor?. Int J Biol Sci, 2009, 5(2): 147152. ［19］ Zhao W, Kruse JP, Tang Y, et al. Negative regulation of the deacetylase SIRT1 by DBC1. Nature, 2008, 451(7178): 587590. ［20］ Kim JE, Chen J, Lou Z. DBC1 is a negative regulator of SIRT1. Nature, 2008, 451(31): 583586. ［21］ Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell, 2008, 14(4): 312323. ［22］ Banks AS, Kon N, Knight C, et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab, 2008, 8(4): 333341. ［23］ Zhang QJ, Wang Z, Chen HZ, et al. Endotheliumspecific overexpression of class Ⅲ deacetylase SIRT1 decreases atherosclerosis in apolipoprotein Edeficient mice. Cardiovasc Res, 2008, 80(2): 191199. ［24］ Pfluger PT, Herranz D, VelascoMiguel S, et al. Sirt1 protects against highfat dietinduced metabolic damage. Proc Natl Acad Sci USA, 2008, 105(28): 97939798. ［25］郭淑芹, 朱春英, 张云良. SIRT1与肿瘤. 国际肿瘤学杂志, 2011, 38(8): 569572. ［26］ Firestein R, Blander G, Michan S, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One, 2008, 3(4): e2020. ［27］ Wang RH, Zheng Y, Kim HS, et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1aggociated tumorigenesis. Mol Cell, 2008, 32(1): 1120. ［28］ Oberdoerffer P, Michan S, McVay M, et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell, 2008, 135(5): 907918.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.

Roles of SIRT1 in tumorigenesis and tumor progression

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments